Innoviva, Inc. (INVA)
$20.74-3.31%Close
BUYRECOVERY · day 10
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.5B
- Beta
- 0.33
- P/E (TTM)
- 4.26
- Short % float
- 9.89%
- Days to cover
- 5.7
- SI change
- -4.2%
- 1W
- -0.43%
- 1M
- -0.77%
- vs SPY 1W
- -0.29%
- vs SPY 1M
- -3.27%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 39
- VALUE
- 47
- GROWTH
- 71
- GARP
- 14
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC18.0%
REV YoY-
ROE30.0%
EPS YoY-
ROA21.0%
GROSS73
OP37
NET81
[VALUATION]
P/E TTM4.26
P/E FWD10.38
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.23
P/FCF-
EV/EBITDA1.60
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E21.87
ALTMAN Z-
CURR RATIO16.01
ND/EBITDA-
BETA0.33
Company news
FAQ
- What is LOPJLB’s current signal on INVA?
- LOPJLB’s latest quantitative signal on Innoviva, Inc. (INVA) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is INVA in?
- Innoviva, Inc. (INVA) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Innoviva, Inc. (INVA) do?
- Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medicatio…